Ceftazidime
Last Updated: 06/30/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 13452 publications
Ralstonia mannitolilytica as a Cause of Postoperative Endophthalmitis.
Journal: Journal of vitreoretinal diseases
Published: June 22, 2026
Epidemiological and clinical characteristics of pertussis in children at a tertiary pediatric hospital in Shanghai City in 2024
Journal: Zhonghua yu fang yi xue za zhi [Chinese journal of preventive medicine]
Published: June 22, 2026
An update on beta-lactam-beta-lactamase inhibitor combinations for the treatment of carbapenem-resistant gram-negative pathogens.
Journal: Expert opinion on drug metabolism & toxicology
Published: June 19, 2026
Streptococcus salivarius endophthalmitis and corneal ring infiltrate after intravitreal bevacizumab injection.
Journal: GMS ophthalmology cases
Published: June 19, 2026
Phase I dose-ascending, safety, and pharmacokinetics study of APC148, a novel metallo-β-lactamase inhibitor, in healthy volunteers.
Journal: Antimicrobial agents and chemotherapy
Published: June 17, 2026
Panophthalmitis With Orbital Cellulitis Following Glaucoma Drainage Implant Surgery in an Adult Patient.
Journal: The American journal of case reports
Published: June 11, 2026
Integron-mediated gene cassette dynamics in Enterobacterales under selective antibiotic pressure.
Journal: Journal of applied microbiology
Published: June 08, 2026
Synergistic potential between camphene, myrcene, and ceftazidime against medically important bacteria.
Journal: Future microbiology
Published: June 02, 2026
Genetic and biochemical characterization of OXA-1054, a carbapenem-hydrolyzing class D β-lactamase conferring broad-spectrum β-lactam resistance in Pseudomonas aeruginosa.
Journal: Antimicrobial agents and chemotherapy
Published: May 29, 2026
Solving the degradation problem of continuous ceftazidime infusions-the Cooltaz study.
Journal: Antimicrobial agents and chemotherapy
Published: May 29, 2026
Comparative activity of ceftibuten combinations with avibactam, ledaborbactam, and xeruborbactam against recombinant β-lactamase-producing Escherichia coli and contemporary WGS-characterized strains of carbapenemase-producing Enterobacterales.
Journal: Antimicrobial agents and chemotherapy
Published: May 29, 2026
Last Updated: 06/30/2026